The pathophysiology of thyroid eye disease

Journal of Neuro-Ophthalmology

Volumn 34, Issue 2, 2014, Pages 177-185

  Shan, Shannon J C ^a   Douglas, Raymond S ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; GAMMA INTERFERON; HYALURONIC ACID; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; SOMATOMEDIN C RECEPTOR; THYROTROPIN RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ADIPOCYTE; AUTOIMMUNITY; CELL ACTIVATION; CELL DIFFERENTIATION; CELL INFILTRATION; CYTOKINE PRODUCTION; EFFECTOR CELL; ENDOCRINE OPHTHALMOPATHY; GRAVES DISEASE; HUMAN; LYMPHOCYTE; MYOFIBROBLAST; NONHUMAN; ORBIT; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; REVIEW; COMPLICATION; EYE DISEASE; IMMUNOLOGY; METABOLISM; PATHOLOGY; THYROID DISEASE; THYROID GLAND;

AUTOANTIBODIES; AUTOANTIGENS; EYE DISEASES; HUMANS; RECEPTOR, IGF TYPE 1; RECEPTORS, THYROTROPIN; THYROID DISEASES; THYROID GLAND;

EID: 84900542574     PISSN: 10708022     EISSN: 15365166     Source Type: Journal    
DOI: 10.1097/WNO.0000000000000132     Document Type: Review

References (130)

1. Bahn RS. Graves ophthalmopathy. N Engl J Med. 2010;362:726-738.
2. Forbes G, Gorman CA, Brennan MD, Gehring DG, Ilstrup DM, Earnest F. Ophthalmopathy of Graves disease: computerized volume measurements of the orbital fat and muscle. AJNR Am J Neuroradiol. 1986;7:651-656.
3. Hufnagel TJ, Hickey WF, Cobbs WH, Jakobiec FA, Iwamoto T, Eagle RC. Immunohistochemical and ultrastructural studies on the exenterated orbital tissues of a patient with Graves disease. Ophthalmology. 1984;91:1411-1419.
4. Smith TJ, Bahn RS, Gorman CA. Connective tissue, glycosaminoglycans, and diseases of the thyroid. Endocr Rev. 1989;10:366-391.
5. Heufelder AE, Smith TJ, Gorman CA, Bahn RS. Increased induction of HLA-DR by interferon-gamma in cultured fibroblasts derived from patients with Graves ophthalmopathy and pretibial dermopathy. J Clin Endocrinol Metab. 1991;73:307-313.
6. Smith RS, Smith TJ, Blieden TM, Phipps RP. Fibroblasts as sentinel cells. Synthesis of chemokines and regulation of inflammation. Am J Pathol. 1997;151:317-322.
7. Bartalena L, Wiersinga WM, Pinchera A. Graves ophthalmopathy: state of the art and perspectives. J Endocrinol Invest. 2004;27:295-301.
8. Smith TJ, Koumas L, Gagnon A, Bell A, Sempowski GD, Phipps RP, Sorisky A. Orbital fibroblast heterogeneity may determine the clinical presentation of thyroid-Associated ophthalmopathy. J Clin Endocrinol Metab. 2002;87:385-392.
9. Wiersinga WM. Autoimmunity in Graves ophthalmopathy: the result of an unfortunate marriage between TSH receptors and IGF-1 receptors? J Clin Endocrinol Metab. 2011;96:2386-2394.
10. Smith TJ, Tsai CC, Shih MJ, Tsui S, Chen B, Han R, Naik V, King CS, Press C, Kamat S, Goldberg RA, Phipps RP, Douglas RS, Gianoukakis AG. Unique attributes of orbital fibroblasts and global alterations in IGF-1 receptor signaling could explain thyroid-Associated ophthalmopathy. Thyroid. 2008;18:983-988.
11. Boschi A, Daumerie C, Spiritus M, Beguin C, Senou M, Yuksel D, Duplicy M, Costagliola S, Ludgate M, Mang MC. Quantification of cells expressing the thyrotropin receptor in extraocular muscles in thyroid associated orbitopathy. Br J Ophthalmol. 2005;89:724-729.
12. Koumas L, Smith TJ, Feldon S, Blumberg N, Phipps RP. Thy-1 expression in human fibroblast subsets defines myofibroblastic or lipofibroblastic phenotypes. Am J Pathol. 2003;163:1291-1300.
13. Koumas L, Smith TJ, Phipps RP. Fibroblast subsets in the human orbit: Thy-1+ and Thy-1-subpopulations exhibit distinct phenotypes. Eur J Immunol. 2002;32:477-485.
14. Sorisky A, Pardasani D, Gagnon A, Smith TJ. Evidence of adipocyte differentiation in human orbital fibroblasts in primary culture. J Clin Endocrinol Metab. 1996;81:3428-3431.
15. Valyasevi RW, Erickson DZ, Harteneck DA, Dutton CM, Heufelder AE, Jyonouchi SC, Bahn RS. Differentiation of human orbital preadipocyte fibroblasts induces expression of functional thyrotropin receptor. J Clin Endocrinol Metab. 1999;84:2557-2562.
16. Valyasevi RW, Harteneck DA, Dutton CM, Bahn RS. Stimulation of adipogenesis, peroxisome proliferatoractivated receptor-gamma (PPARgamma), and thyrotropin receptor by PPARgamma agonist in human orbital preadipocyte fibroblasts. J Clin Endocrinol Metab. 2002;87:2352-2358.
17. Feldon SE, OLoughlin CW, Ray DM, Landskroner-Eiger S, Seweryniak KE, Phipps RP. Activated human T lymphocytes express cyclooxygenase-2 and produce proadipogenic prostaglandins that drive human orbital fibroblast differentiation to adipocytes. Am J Pathol. 2006;169:1183-1193.
18. Bahn RS. Clinical review 157: pathophysiology of Graves ophthalmopathy: the cycle of disease. J Clin Endocrinol Metab. 2003;88:1939-1946.
19. Korducki JM, Loftus SJ, Bahn RS. Stimulation of glycosaminoglycan production in cultured human retroocular fibroblasts. Invest Ophthalmol Vis Sci. 1992;33:2037-2042.
20. Smith TJ, Wang HS, Evans CH. Leukoregulin is a potent inducer of hyaluronan synthesis in cultured human orbital fibroblasts. Am J Physiol. 1995;268:C382-C388.
21. Cao HJ, Wang HS, Zhang Y, Lin HY, Phipps RP, Smith TJ. Activation of human orbital fibroblasts through CD40 engagement results in a dramatic induction of hyaluronan synthesis and prostaglandin endoperoxide H synthase-2 expression. Insights into potential pathogenic mechanisms of thyroid-Associated ophthalmopathy. J Biol Chem. 1998;273:29615-29625.
22. Kaback LA, Smith TJ. Expression of hyaluronan synthase messenger ribonucleic acids and their induction by interleukin-1beta in human orbital fibroblasts: potential insight into the molecular pathogenesis of thyroid-Associated ophthalmopathy. J Clin Endocrinol Metab. 1999;84:4079-4084.
23. Han R, Smith TJ. T helper type 1 and type 2 cytokines exert divergent influence on the induction of prostaglandin E2 and hyaluronan synthesis by interleukin-1beta in orbital fibroblasts: implications for the pathogenesis of thyroid-Associated ophthalmopathy. Endocrinology. 2006;147:13-19.
24. Spicer AP, Kaback LA, Smith TJ, Seldin MF. Molecular cloning and characterization of the human and mouse UDP-glucose dehydrogenase genes. J Biol Chem. 1998;273:25117-25124.
25. Smith TJ, Hoa N. Immunoglobulins from patients with Graves disease induce hyaluronan synthesis in their orbital fibroblasts through the self-Antigen, insulin-like growth factor-I receptor. J Clin Endocrinol Metab. 2004;89:5076-5080.
26. Krieger CC, Gershengorn MC. A modified ELISA accurately measures secretion of high molecular weight hyaluronan (HA) by Graves disease orbital cells. Endocrinology. 2014;155:627-634.
27. Tan GH, Dutton CM, Bahn RS. Interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptor inhibit IL-1-induced glycosaminoglycan production in cultured human orbital fibroblasts from patients with Graves ophthalmopathy. J Clin Endocrinol Metab. 1996;81:449-452.
28. Heufelder AE, Bahn RS. Modulation of Graves orbital fibroblast proliferation by cytokines and glucocorticoid receptor agonists. Invest Ophthalmol Vis Sci. 1994;35:120-127.
29. Han R, Tsui S, Smith TJ. Up-regulation of prostaglandin E2 synthesis by interleukin-1beta in human orbital fibroblasts involves coordinate induction of prostaglandin-endoperoxide H synthase-2 and glutathione-dependent prostaglandin E2 synthase expression. J Biol Chem. 2002;277:16355-16364.
30. Wang HS, Cao HJ, Winn VD, Rezanka LJ, Frobert Y, Evans CH, Sciaky D, Young DA, Smith TJ. Leukoregulin induction of prostaglandin-endoperoxide H synthase-2 in human orbital fibroblasts. An in vitro model for connective tissue inflammation. J Biol Chem. 1996;271:22718-22728.
31. Cao HJ, Smith TJ. Leukoregulin upregulation of prostaglandin endoperoxide H synthase-2 expression in human orbital fibroblasts. Am J Physiol. 1999;277:C1075-C1085.
32. Young DA, Evans CH, Smith TJ. Leukoregulin induction of protein expression in human orbital fibroblasts: evidence for anatomical site-restricted cytokine-target cell interactions. Proc Natl Acad Sci U S A. 1998;95:8904-8909.
33. Hwang CJ, Afifiyan N, Sand D, Naik V, Said J, Pollock SJ, Chen B, Phipps RP, Goldberg RA, Smith TJ, Douglas RS. Orbital fibroblasts from patients with thyroid-Associated ophthalmopathy overexpress CD40: CD154 hyperinduces IL-6, IL-8, and MCP-1. Invest Ophthalmol Vis Sci. 2009;50:2262-2268.
34. Sciaky D, Brazer W, Center DM, Cruikshank WW, Smith TJ. Cultured human fibroblasts express constitutive IL-16 mRNA: cytokine induction of active IL-16 protein synthesis through a caspase-3-dependent mechanism. J Immunol. 2000;164:3806-3814.
35. Bucala R, Spiegel LA, Chesney J, Hogan M, Cerami A. Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol Med. 1994;1:71-81.
36. Chesney J, Bacher M, Bender A, Bucala R. The peripheral blood fibrocyte is a potent antigen-presenting cell capable of priming naive T cells in situ. Proc Natl Acad Sci U S A. 1997;94:6307-6312.
37. Quan TE, Cowper S, Wu SP, Bockenstedt LK, Bucala R. Circulating fibrocytes: collagen-secreting cells of the peripheral blood. Int J Biochem Cell Biol. 2004;36:598-606.
38. Peng H, Herzog EL. Fibrocytes: emerging effector cells in chronic inflammation. Curr Opin Pharmacol. 2012;12:491-496.
39. Douglas RS, Afifiyan NF, Hwang CJ, Chong K, Haider U, Richards P, Gianoukakis AG, Smith TJ. Increased generation of fibrocytes in thyroid-Associated ophthalmopathy. J Clin Endocrinol Metab. 2010;95:430-438.
40. Smith TJ, Padovani-Claudio DA, Lu Y, Raychaudhuri N, Fernando R, Atkins S, Gillespie EF, Gianoukakis AG, Miller BS, Gauger PG, Doherty GM, Douglas RS. Fibroblasts expressing the thyrotropin receptor overarch thyroid and orbit in Graves disease. J Clin Endocrinol Metab. 2011;96:3827-3837.
41. Hong KM, Belperio JA, Keane MP, Burdick MD, Strieter RM. Differentiation of human circulating fibrocytes as mediated by transforming growth factor-beta and peroxisome proliferatoractivated receptor gamma. J Biol Chem. 2007;282:22910-22920.
42. Gillespie EF, Papageorgiou KI, Fernando R, Raychaudhuri N, Cockerham KP, Charara LK, Goncalves AC, Zhao SX, Ginter A, Lu Y, Smith TJ, Douglas RS. Increased expression of TSH receptor by fibrocytes in thyroid-Associated ophthalmopathy leads to chemokine production. J Clin Endocrinol Metab. 2012;97:E740-E746.
43. Hutfless S, Matos P, Talor MV, Caturegli P, Rose NR. Significance of prediagnostic thyroid antibodies in women with autoimmune thyroid disease. J Clin Endocrinol Metab. 2011;96:E1466-E1471.
44. Ludgate M, Swillens S, Mercken L, Vassart G. Homology between thyroglobulin and acetylcholinesterase: an explanation for pathogenesis of Graves ophthalmopathy? Lancet. 1986;2:219-220.
45. Mizokami T, Salvi M, Wall JR. Eye muscle antibodies in Graves ophthalmopathy: pathogenic or secondary epiphenomenon? J Endocrinol Invest. 2004;27:221-229.
46. Gunji K, Kubota S, Stolarski C, Wengrowicz S, Kennerdell JS, Wall JR. A 63 kDa skeletal muscle protein associated with eye muscle inflammation in Graves disease is identified as the calcium binding protein calsequestrin. Autoimmunity. 1999;29:1-9.
47. Gerding MN, van der Meer JW, Broenink M, Bakker O, Wiersinga WM, Prummel MF. Association of thyrotrophin receptor antibodies with the clinical features of Graves ophthalmopathy. Clin Endocrinol (Oxf). 2000;52:267-271.
48. Eckstein AK, Plicht M, Lax H, Hirche H, Quadbeck B, Mann K, Steuhl KP, Esser J, Morganthaler NG. Clinical results of antiinflammatory therapy in Graves ophthalmopathy and association with thyroidal autoantibodies. Clin Endocrinol (Oxf). 2004;61:612-618.
49. Khoo TK, Bahn RS. Pathogenesis of Graves ophthalmopathy: the role of autoantibodies. Thyroid. 2007;17:1013-1018.
50. Weetman AP. Graves disease. N Engl J Med. 2000;343:1236-1248.
51. Ponto KA, Kanitz M, Olivo PD, Pitz S, Pfeiffer N, Kahaly GJ. Clinical relevance of thyroid-stimulating immunoglobulins in Graves ophthalmopathy. Ophthalmology. 2011;118:2279-2285.
52. Eckstein AK, Plicht M, Lax H, Neuhauser M, Mann K, Lederbogen S, Heckmann C, Esser J, Morgenthaler NG. Thyrotropin receptor autoantibodies are independent risk factors for Graves ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab. 2006;91:3464-3470.
53. Lytton SD, Ponto KA, Kanitz M, Matheis N, Kohn LD, Kahaly GJ. A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves orbitopathy. J Clin Endocrinol Metab. 2010;95:2123-2131.
54. Davies T, Marians R, Latif R. The TSH receptor reveals itself. J Clin Invest. 2002;110:161-164.
55. Starkey KJ, Janezic A, Jones G, Jordan N, Baker G, Ludgate M. Adipose thyrotrophin receptor expression is elevated in Graves and thyroid eye diseases ex vivo and indicates adipogenesis in progress in vivo. J Mol Endocrinol. 2003;30:369-380.
56. Bahn RS, Dutton CM, Natt N, Joba W, Spitzweg C, Heufelder AE. Thyrotropin receptor expression in Graves orbital adipose/connective tissues: potential autoantigen in Graves ophthalmopathy. J Clin Endocrinol Metab. 1998;83:998-1002.
57. Crisp MS, Lane C, Halliwell M, Wynford-Thomas D, Ludgate M. Thyrotropin receptor transcripts in human adipose tissue. J Clin Endocrinol Metab. 1997;82:2003-2005.
58. Stadlmayr W, Spitzweg C, Bichlmair AM, Heufelder AE. TSH receptor transcripts and TSH receptor-like immunoreactivity in orbital and pretibial fibroblasts of patients with Graves ophthalmopathy and pretibial myxedema. Thyroid. 1997;7:3-12.
59. Wakelkamp IM, Bakker O, Baldeschi L, Wiersinga WM, Prummel MF. TSH-R expression and cytokine profile in orbital tissue of active vs. inactive Graves ophthalmopathy patients. Clin Endocrinol (Oxf). 2003;58:280-287.
60. Kumar S, Nadeem S, Stan MN, Coenen M, Bahn RS. A stimulatory TSH receptor antibody enhances adipogenesis via phosphoinositide 3-kinase activation in orbital preadipocytes from patients with Graves ophthalmopathy. J Mol Endocrinol. 2011;46:155-163.
61. Jyonouchi SC, Valyasevi RW, Harteneck DA, Dutton CM, Bahn RS. Interleukin-6 stimulates thyrotropin receptor expression in human orbital preadipocyte fibroblasts from patients with Graves ophthalmopathy. Thyroid. 2001;11:929-934.
62. Kumar S, Coenen MJ, Scherer PE, Bahn RS. Evidence for enhanced adipogenesis in the orbits of patients with Graves ophthalmopathy. J Clin Endocrinol Metab. 2004;89:930-935.
63. Turcu AF, Kumar S, Neumann S, Coenen M, Iyer S, Chiriboga P, Gershengoin MC, Bahn RS. A small molecule antagonist inhibits thyrotropin receptor antibody-induced orbital fibroblast functions involved in the pathogenesis of Graves ophthalmopathy. J Clin Endocrinol Metab. 2013;98:2153-2159.
64. Zhang L, Baker G, Janus D, Paddon CA, Fuhrer D, Ludgate M. Biological effects of thyrotropin receptor activation on human orbital preadipocytes. Invest Ophthalmol Vis Sci. 2006;47:5197-5203.
65. Zhang L, Bowen T, Grennan-Jones F, Paddon C, Giles P, Webber J, Steadman R, Ludgate M. Thyrotropin receptor activation increases hyaluronan production in preadipocyte fibroblasts: contributory role in hyaluronan accumulation in thyroid dysfunction. J Biol Chem. 2009;284: 26447-26455.
66. McLachlan SM, Nagayama Y, Rapoport B. Insight into Graves hyperthyroidism from animal models. Endocr Rev. 2005;26:800-832.
67. Ludgate M. Animal models of Graves disease. Eur J Endocrinol. 2000;142:1-8.
68. Dagdelen S, Kong YC, Banga JP. Toward better models of hyperthyroid Graves disease. Endocrinol Metab Clin North Am. 2009;38:343-354. viii.
69. Wiesweg B, Johnson KT, Eckstein AK, Berchner-Pfannschmidt U. Current insights into animal models of Graves disease and orbitopathy. Horm Metab Res. 2013;45:549-555.
70. Baker G, Mazziotti G, von Ruhland C, Ludgate M. Reevaluating thyrotropin receptor-induced mouse models of Graves disease and ophthalmopathy. Endocrinology. 2005;146:835-844.
71. Moshkelgosha S, So PW, Deasy N, Diaz-Cano S, Banga JP. Cutting edge: retrobulbar inflammation, adipogenesis, and acute orbital congestion in a preclinical female mouse model of Graves orbitopathy induced by thyrotropin receptor plasmid-in vivo electroporation. Endocrinology. 2013;154:3008-3015.
72. Rickards C, Buckland P, Smith BR, Hall R. The interaction of Graves IgG with the thyrotrophin receptor. FEBS Lett. 1981;127:17-21.
73. Smith TJ, Hegedus L, Douglas RS. Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves orbitopathy. Best Pract Res Clin Endocrinol Metab. 2012;26:291-302.
74. Smith TJ. Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases? Pharmacol Rev. 2010;62:199-236.
75. Bateman JM, McNeill H. Insulin/IGF signalling in neurogenesis. Cell Mol Life Sci. 2006;63:1701-1705.
76. Kurmasheva RT, Houghton PJ. IGF-I mediated survival pathways in normal and malignant cells. Biochim Biophys Acta. 2006;1766:1-22.
77. Walenkamp MJ, Wit JM. Genetic disorders in the growth hormone -insulin-like growth factor-I axis. Horm Res. 2006;66:221-230.
78. Tsui S, Naik V, Hoa N, Hwang CJ, Afifiyan NF, Sinha Hikim A, Gianoukakis AG, Douglas RS, Smith TJ. Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves disease. J Immunol. 2008;181:4397-4405.
79. Imai Y, Odajima R, Inoue Y, Shishiba Y. Effect of growth factors on hyaluronan and proteoglycan synthesis by retroocular tissue fibroblasts of Graves ophthalmopathy in culture. Acta Endocrinol (Copenh). 1992;126:541-552.
80. Pritchard J, Horst N, Cruikshank W, Smith TJ. Igs from patients with Graves disease induce the expression of T cell chemoattractants in their fibroblasts. J Immunol. 2002;168:942-950.
81. Pritchard J, Han R, Horst N, Cruikshank WW, Smith TJ. Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves disease is mediated through the insulin-like growth factor I receptor pathway. J Immunol. 2003;170:6348-6354.
82. Weightman DR, Perros P, Sherif IH, Kendall-Taylor P. Autoantibodies to IGF-1 binding sites in thyroid associated ophthalmopathy. Autoimmunity. 1993;16:251-257.
83. Jonas HA, Harrison LC. The human placenta contains two distinct binding and immunoreactive species of insulin-like growth factor-I receptors. J Biol Chem. 1985;260:2288-2294.
84. Rosenfeld RG, Dollar LA. Characterization of the somatomedin-C/insulin- like growth factor I (SM-C/IGF-I) receptor on cultured human fibroblast monolayers: regulation of receptor concentrations by SM-C/IGF-I and insulin. J Clin Endocrinol Metab. 1982;55:434-440.
85. Tollefsen SE, Thompson K, Petersen DJ. Separation of the high affinity insulin-like growth factor I receptor from low affinity binding sites by affinity chromatography. J Biol Chem. 1987;262:16461-16469.
86. Minich WB, Dehina N, Welsink T, Schwiebert C, Morgenthaler NG, Kohrle J, Eckstein A, Schomburg L. Autoantibodies to the IGF1 receptor in Graves orbitopathy. J Clin Endocrinol Metab. 2013;98:752-760.
87. Zhao SX, Tsui S, Cheung A, Douglas RS, Smith TJ, Banga JP. Orbital fibrosis in a mouse model of Graves disease induced by genetic immunization of thyrotropin receptor cDNA. J Endocrinol. 2011;210:369-377.
88. Kimura T, Van Keymeulen A, Golstein J, Fusco A, Dumont JE, Roger PP. Regulation of thyroid cell proliferation by TSH and other factors: a critical evaluation of in vitro models. Endocr Rev. 2001;22:631-656.
89. Tramontano D, Cushing GW, Moses AC, Ingbar SH. Insulinlike growth factor-I stimulates the growth of rat thyroid cells in culture and synergizes the stimulation of DNA synthesis induced by TSH and Graves-IgG. Endocrinology. 1986;119:940-942.
90. Rapoport B, McLachlan SM. The thyrotropin receptor in Graves disease. Thyroid. 2007;17:911-922.
91. Kohn LD, Alvarez F, Marcocci C, Kohn AD, Corda D, Hoffman WE, Tombaccini D, Valente WA, de Luca M, Santisteban P, Grollman EF. Monoclonal antibody studies defining the origin and properties of autoantibodies in Graves disease. Ann N Y Acad Sci. 1986;475:157-173.
92. Kumar S, Iyer S, Bauer H, Coenen M, Bahn RS. A stimulatory thyrotropin receptor antibody enhances hyaluronic acid synthesis in Graves orbital fibroblasts: inhibition by an IGF-I receptor blocking antibody. J Clin Endocrinol Metab. 2012;97:1681-1687.
93. McLachlan SM, Rapoport B. Breaking tolerance to thyroid antigens: changing concepts in thyroid autoimmunity. Endocr Rev. 2014;35:59-105.
94. Janeway CA Jr, Travers P, Walport M, Shlomchik MJ. Immunobiology: The Immune System in Health and Disease, 5th edition. New York, NY: Garland Science, 2001.
95. Sempowski GD, Rozenblit J, Smith TJ, Phipps RP. Human orbital fibroblasts are activated through CD40 to induce proinflammatory cytokine production. Am J Physiol. 1998;274:C707-C714.
96. Grewal IS, Flavell RA. The role of CD40 ligand in costimulation and T-cell activation. Immunol Rev. 1996;153:85-106.
97. Feldon SE, Park DJ, OLoughlin CW, Nguyen VT, Landskroner-Eiger S, Chang D, Thatcher TH, Phipps RP. Autologous T-lymphocytes stimulate proliferation of orbital fibroblasts derived from patients with Graves ophthalmopathy. Invest Ophthalmol Vis Sci. 2005;46:3913-3921.
98. Ueki I, Abiru N, Kobayashi M, Nakahara M, Ichikawa T, Eguchi K, Nagayama Y. B cell-targeted therapy with anti-CD20 monoclonal antibody in a mouse model of Graves hyperthyroidism. Clin Exp Immunol. 2011;163:309-317.
99. Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol. 2003;14:520-535.
100. Vannucchi G, Campi I, Bonomi M, Covelli D, Dazzi D, Curro N, Simonetta S, Bonara P, Personi L, Guastella C, Wall J, Beck-Peccozi P, Salvi M. Rituximab treatment in patients with active Graves orbitopathy: effects on proinflammatory and humoral immune reactions. Clin Exp Immunol. 2010;161:436-443.
101. Bonara P, Vannucchi G, Campi I, Rossi S, Cantoni F, Frugoni C, Sbrozzi F, Guastella Cm Avignone S, Beck-Peccoz P, Salvi M. Rituximab induces distinct intraorbital and intrathyroidal effects in one patient satisfactorily treated for Graves ophthalmopathy. Clin Rev Allergy Immunol. 2008;34:118-123.
102. Salvi M, Vannucchi G, Campi I, Curro N, Dazzi D, Simonetta S, Bonara P, Rossi I, Sina C. Treatment of Graves disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur J Endocrinol. 2007;156:33-40.
103. Salvi M, Vannucchi G, Campi I, Beck-Peccoz P. Rituximab in the treatment of thyroid eye disease: science fiction? Orbit. 2009;28:251-255.
104. Silkiss RZ, Reier A, Coleman M, Lauer SA. Rituximab for thyroid eye disease. Ophthal Plast Reconstr Surg. 2010;26:310-314.
105. Salvi M, Vannucchi G, Curro N, Introna M, Rossi S, Bonara P, Covelli D, Dazzi D, Guastella C, Pignataro L, Ratiglia R, Golay J, Beck-Peccoz P. Small dose of rituximab for Graves orbitopathy: new insights into the mechanism of action. Arch Ophthalmol. 2012;130:122-124.
106. Minakaran N, Ezra DG. Rituximab for thyroid-Associated ophthalmopathy. Cochrane Database Syst Rev. 2013;5: CD009226.
107. Douglas RS, Gianoukakis AG, Kamat S, Smith TJ. Aberrant expression of the insulin-like growth factor-1 receptor by T cells from patients with Graves disease may carry functional consequences for disease pathogenesis. J Immunol. 2007;178:3281-3287.
108. Douglas RS, Naik V, Hwang CJ, Afifiyan NF, Gianoukakis AG, Sand D, Kamat S, Smith TJ. B cells from patients with Graves disease aberrantly express the IGF-1 receptor: implications for disease pathogenesis. J Immunol. 2008;181:5768-5674-5774.
109. Douglas RS, Brix TH, Hwang CJ, Hegedus L, Smith TJ. Divergent frequencies of IGF-I receptor-expressing blood lymphocytes in monozygotic twin pairs discordant for Graves disease: evidence for a phenotypic signature ascribable to nongenetic factors. J Clin Endocrinol Metab. 2009;94:1797-1802.
110. Gianoukakis AG, Khadavi N, Smith TJ. Cytokines, Graves disease, and thyroid-Associated ophthalmopathy. Thyroid. 2008;18:953-958.
111. Hiromatsu Y, Yang D, Bednarczuk T, Miyake I, Nonaka K, Inoue Y. Cytokine profiles in eye muscle tissue and orbital fat tissue from patients with thyroid-Associated ophthalmopathy. J Clin Endocrinol Metab. 2000;85: 1194-1199.
112. Pappa A, Calder V, Ajjan R, Fells P, Ludgate M, Weetman AP, Lightman S. Analysis of extraocular muscle-infiltrating T cells in thyroid-Associated ophthalmopathy (TAO). Clin Exp Immunol. 1997;109:362-369.
113. Heufelder AE, Bahn RS. Detection and localization of cytokine immunoreactivity in retro-ocular connective tissue in Graves ophthalmopathy. Eur J Clin Invest. 1993;23:10-17.
114. Natt N, Bahn RS. Cytokines in the evolution of Graves ophthalmopathy. Autoimmunity. 1997;26:129-136.
115. Kumar S, Bahn RS. Relative overexpression of macrophagederived cytokines in orbital adipose tissue from patients with Graves ophthalmopathy. J Clin Endocrinol Metab. 2003;88:4246-4250.
116. van Steensel L, Paridaens D, van Meurs M, van Hagen PM, van den Bosch WA, Kuijpers RW, Drexhage HA, Hooijkaas H, Dik WA. Orbit-infiltrating mast cells, monocytes, and macrophages produce PDGF isoforms that orchestrate orbital fibroblast activation in Graves ophthalmopathy. J Clin Endocrinol Metab. 2012;97:E400-E408.
117. Berger A. Th1 and Th2 responses: what are they? BMJ. 2000;321:424.
118. Prabhakar BS, Bahn RS, Smith TJ. Current perspective on the pathogenesis of Graves disease and ophthalmopathy. Endocr Rev. 2003;24:802-835.
119. Aniszewski JP, Valyasevi RW, Bahn RS. Relationship between disease duration and predominant orbital T cell subset in Graves ophthalmopathy. J Clin Endocrinol Metab. 2000;85:776-780.
120. de Carli M, DElios MM, Mariotti S, Marcocci C, Pinchera A, Ricci M, Romagnani S, del Prete G. Cytolytic T cells with Th1-like cytokine profile predominate in retroorbital lymphocytic infiltrates of Graves ophthalmopathy. J Clin Endocrinol Metab. 1993;77:1120-1124.
121. Chiaramonte MG, Donaldson DD, Cheever AW, Wynn TA. An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2-dominated inflammatory response. J Clin Invest. 1999;104:777-785.
122. Hasegawa M, Fujimoto M, Kikuchi K, Takehara K. Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J Rheumatol. 1997;24:328-332.
123. Kanellakis P, Ditiatkovski M, Kostolias G, Bobik A. A profibrotic role for interleukin-4 in cardiac pressure overload. Cardiovasc Res. 2012;95:77-85.
124. Lee CG, Homer RJ, Zhu Z, Lanone S, Wang X, Koteliansky V, Shipley JM, Gotwais P, Noble P, Chen Q, Senior RM, Elias JA. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1). J Exp Med. 2001;194:809-821.
125. OReilly S. Role of interleukin-13 in fibrosis, particularly systemic sclerosis. Biofactors. 2013;39:593-596.
126. Shimamura T, Fujisawa T, Husain SR, Kioi M, Nakajima A, Puri RK. Novel role of IL-13 in fibrosis induced by nonalcoholic steatohepatitis and its amelioration by IL-13R-directed cytotoxin in a rat model. J Immunol. 2008;181:4656-4665.
127. Wu D, Ahrens R, Osterfeld H, Noah TK, Groschwitz K, Foster PS, Steinbrecher KA, Rothenberg ME, Stroyer NF, Matthaei KI, Finkelman FD, Hogan SP. Interleukin-13 (IL-13)/ IL-13 receptor alpha1 (IL-13Ralpha1) signaling regulates intestinal epithelial cystic fibrosis transmembrane conductance regulator channel-dependent Cl-secretion. J Biol Chem. 2011;286:13357-13369.
128. Zhu Z, Homer RJ, Wang Z, Chen Q, Geba GP, Wang J, Zhang Y, Elias JA. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest. 1999;103:779-788.
129. van Steensel L, Paridaens D, Dingjan GM, van Daele PL, van Hagen PM, Kuijpers RW, van den Bosch WA, Drexhage HA, Hooijkaas H, Dik WA. Platelet-derived growth factor-BB: a stimulus for cytokine production by orbital fibroblasts in Graves ophthalmopathy. Invest Ophthalmol Vis Sci. 2010;51:1002-1007.
130. Cao HJ, Han R, Smith TJ. Robust induction of PGHS-2 by IL-1 in orbital fibroblasts results from low levels of IL-1 receptor antagonist expression. Am J Physiol Cell Physiol. 2003;284: C1429-C1437